Compare Abeona Therapeutics Inc (ABEO) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ProShares UltraPro QQQ ETF — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while ProShares UltraPro QQQ ETF trades at $72.22. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | TQQQ | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $87.22 |
52-Week Low | $4.17 | $37.89 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TQQQ trades at $76.42, up 4.19% with a neutral technical signal. The leveraged ETF shows bullish moving averages but faces structural costs that compound daily, as highlighted in recent analysis. Recent news emphasizes both the potential for amplified returns and significant drawdown risks during market volatility.
The outlook remains volatile-dependent; while historical performance shows substantial gains in bull markets, the 3x leverage magnifies losses during downturns. Key risks include daily reset mechanics and compounding costs, requiring careful position sizing and risk management for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
